Silence Therapeutics signs collaboration with MiReven Pty Ltd to evaluate delivery of novel microRNA-based therapeutics

Silence Therapeutics signs collaboration with MiReven Pty Ltd to evaluate delivery of novel microRNA-based therapeutics
-- Fourth collaboration to investigate the potential application of Silence's proprietary delivery technologies in the development of novel microRNA-based therapeutics --


London, UK, August 22, 2012 – Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with MiReven Pty Ltd ("MiReven"), to assess the delivery potential of Silence's proprietary delivery systems with MiReven's novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7.
Under the terms of the agreement, Silence will formulate a miR-7 mimetic (a potentially therapeutic mimic of the miR-7 molecule) with its proprietary AtuPLEX™, DACC and DBTC delivery systems in order to evaluate miR-7 in various cancer models. Silence will undertake in vitro and in vivo studies of the formulated miR-7. Silence is being paid an undisclosed fee for the collaboration.

AtuPLEX™, DACC and DBTC are proprietary RNAi delivery systems developed by Silence.

Silence's most advanced lipid delivery technology, AtuPLEX™, has demonstrated broad systemic delivery to the vascular endothelium. The AtuPLEX™ delivery system is used in Atu027, Silence's lead oncology candidate in Phase I trials. DACC, closely related to AtuPLEX™, is a novel lipid delivery system that enables functional, highly specific and efficient delivery of RNAi therapeutics to the pulmonary vascular endothelium. DBTC is a novel lipid-based formulation that functionally delivers siRNA to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.

Klaus Giese, Chief Scientific Officer of Silence Therapeutics, said: "We are delighted to be collaborating with MiReven. This is the fourth collaboration that we have recently signed to explore the use of Silence's delivery technologies for microRNAs. Whilst we remain internally focused on the delivery of our siRNA therapies, we continue to broaden the potential value of our proprietary delivery systems by collaborating with partners. Functional delivery to target cells is widely recognized as one of the greatest challenges facing most nucleic acid therapies. Our three proprietary RNAi delivery systems, AtuPLEX™, DACC and DBTC, deliver effective doses of RNAi to key intracellular targets in vascular endothelium, lung and liver respectively, and provide our partners with a growing range of solutions to overcome their delivery challenges."

Stephen Thompson of MiReven Pty Ltd, said: "MiReven's founding scientists have developed a compelling body of preclinical data supporting the potential of miR-7 to suppress tumour growth, particularly in the many cancers known to be controlled by the EGF receptor signaling pathway including glioblastoma. MiReven is currently testing drug-like versions of miR-7 in key models of human cancer."

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.